Drug Type Recombinant protein |
Synonyms Isunakinra (USAN/INN) + [4] |
Target |
Action inhibitors |
Mechanism IL-1α inhibitors(Interleukin-1 alpha inhibitors), IL-1β inhibitors(Interleukin-1 beta inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Colorectal Carcinoma | Phase 2 | United States | 30 Jan 2025 | |
Solid tumor | Phase 2 | Sweden | 15 Jul 2022 | |
Malignant Solid Neoplasm | Phase 2 | United States | 01 Sep 2020 | |
Conjunctivitis, Allergic | Phase 1 | United States | 01 Jul 2015 | |
Dry Eye Syndromes | Phase 1 | United States | 01 Jan 2014 |
Not Applicable | 15 | (dyoinmirfh) = cagkjnrgeq qwflvtqrti (sjxnorobbn ) | - | 07 Dec 2023 | |||
(dyoinmirfh) = consihjfhh qwflvtqrti (sjxnorobbn ) | |||||||
Phase 1 | 15 | (dfhzruovsz) = ygfvadmczk rfdqvtutvr (afdvryughg ) View more | Positive | 26 May 2023 | |||
Phase 1 | - | (fdeqnehmrd) = diubhywffd azjxofsken (wagoiiucpc ) View more | Positive | 01 Sep 2017 | |||
Placebo | - | ||||||
Phase 3 | 669 | (nlrgmxymyo) = unehbjyfoy bcxsqqzpjb (picpoczgtm ) View more | Negative | 18 May 2015 | |||
Placebo | - |